SPG20 antibody (N-Term)
Quick Overview for SPG20 antibody (N-Term) (ABIN954908)
Target
See all SPG20 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 24-54, N-Term
-
Specificity
- This antibody recognizes Spartin / SPG20 at N-term.
-
Cross-Reactivity (Details)
- Species reactivity (tested):Human
-
Purification
- Purified through a Protein A column followed by peptide affinity purification
-
Immunogen
- Synthetic peptide - KLH conjugated - corresponding to the N-terminal region (between 24-54aa) of human Spartin / SPG20
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) Sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
-
Alternative Name
- Spartin / SPG20
-
Background
- Spartin / SPG20 is a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor.Synonyms: KIAA0610, Spastic paraplegia 20 protein, TAHCCP1, Trans-activated by hepatitis C virus core protein 1
-
Gene ID
- 23111
-
NCBI Accession
- NP_001135766
-
Pathways
- Regulation of Cell Size, SARS-CoV-2 Protein Interactome
Target
-